Primary Product
NKA01 - A novel drug to prolong life after injury & blood loss
Future Users
Military Medics, Ambulances, Hospitals, Surgeons, Strategic Stockpiles
Stage & Sector
Early-Stage Biotech w/ Proof of Concept in Small Animal Studies
Our Focus
Lead Optimization of NKA01, an antibody designed to neutralize the Shock Toxin
What is Shock?
The Definition
Our body’s stress response to blood loss (hemorrhage).
The Causes
Car Crashes, Gun Shot Wounds, Burns, & Combat Injuries
The Symptoms
Low blood pressure & high potassium; commonly fatal.
The Impact
Injury is the #1 Cause of Death People Ages 1 - 44 in the United States
Future
We Believe in a Better Future for Patients in Shock
NKA Bio Believes in a Future Where...
You are administered NKA01 at the scene of injury to allow for more time to get to a hospital before shock kills you.
NKA01 keeps you alive long enough for trauma teams to stop the bleeding and repair your injuries.
You can survive shock, giving you the opportunity to recover from an otherwise fatal injury & return home to your family.
Market
Every day, medical professionals in the US run out of time and patients bleed to death. On average:
-
148,000 people die every year from hemorrhage-related injuries.
-
Annually, 211,530 hemorrhage-related patients admitted to trauma center ICUs.
-
In the US, most hemorrhage-related trauma patients spend 3-4 days in the ICU.
-
Reducing ICU care would save a per-patient average of $4,300 per day.
A drug to resuscitate and stabilize patients in shock, would create an opportunity to save lives and reduce trauma care costs.
Hemorrhagic Shock
4M
People Killed Globally by Trauma Associated with Injury & Violence
World Health Organization
Cardiogenic Shock
14M
People Killed Globally by Cardiac Insults Including Heart Attacks and Strokes
World Health Organization
Circulatory Shock is a Global Problem
Pipeline
NKA Bio's Critical Care Pipeline
Product
Indication
Discovery
Lead
Optimization
Safety
Toxicology
Hemorrhagic
Shock
NKA01
Septic Shock
(Endotoxic)
NKA02
NKA03
Acute Lung Injury
& ARDS
NKA04
Heart Attack
Resuscitation
All IP is Owned by NKA Bio, and All Programs are Available for Licensing & Partnership
World Health Organization
Team
Shock Pioneer Behind Discovery
(1932 - 2020)
Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.
Donald S.
Gann, MD
Susan
Gann Hibbs
Chief Executive Officer
Corporate Vision
Investor Relations
Corporate Operations
Lewis C.
Hibbs III
Chief Operating Officer
R&D Operations
Antibody Engineering
Research & Grant Writing
Les E.
Johnson
Chief Technology Officer
Global Drug Development
Regulatory Lead
Quality & Risk Management
SUPPORT
Advisors
Military Medicine
